On November 1, 2023 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, reported the presentation of six studies at the upcoming SITC (Free SITC Whitepaper) (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California (Press release, Lunit, NOV 1, 2023, View Source [SID1234636678]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During this year’s meeting, Lunit plans to highlight the predictive value and analytical power of its Lunit SCOPE suite in various types of cancer, such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
A collaborative study with the Samsung Medical Center assessed tumor-infiltrating lymphocytes (TILs) using AI-powered spatial analysis with Lunit SCOPE IO in EGFR-mutated non-small cell lung cancer (NSCLC) patients pre- and post-tyrosine kinase inhibitors (TKI) treatment. The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes. Patients with an inflamed immune phenotype after EGFR-TKI treatment showed a more favorable response to subsequent immune checkpoint inhibitors (ICI) treatment. The study found that inflamed immune phenotype after EGFR-TKI treatment showed a higher overall response (OR; 40.0% vs. 7.5%) and better progression-free survival (PFS; 4.1 vs. 1.4 months) than other immune phenotype groups (excluded and desert type) to ICI treatment.
In another study, Lunit assessed the distribution of TILs in six subtypes of triple-negative breast cancer (TNBC) and their association with driver mutations. By analyzing The Cancer Genome Atlas breast cancer dataset using Lunit SCOPE IO, the study found that the immunomodulatory (IM) subtype of TNBC has a significantly higher mean intratumoral (iTIL), stromal (sTIL), and total TIL (tTIL) score than other TNBC subtypes. Additionally, TNBC samples with PIK3CA mutation/amplification or PTEN loss and BRCA1 or BRCA2 mutation each showed a higher total TIL score than those without mutation. This demonstrates that the TIL distribution can be a valuable biomarker for navigating the optimal treatment strategy in TNBC.
Lunit also explored the correlation between methylation burden and AI-based immune phenotype in The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas dataset, which included 22 tumor types and a total of 6243 samples. The study found that the degree of methylation aberrancy in cancer is linked with TIL infiltration in the tumor microenvironment (TME) assessed by Lunit SCOPE IO.
Another study investigated the effect of tumor fragmentation index (TFI), the number of tumor fragments per total tumor area, in TME. In the study, a total of 7,472 TCGA H&E whole-slide images across 23 cancer types were analyzed with Lunit SCOPE IO. The study found that tumors with high TFI are closely correlated with high fibroblast infiltration but showed low IFNG, IL1A, and IL17A, genes that trigger inflammation as cancer grows.
"We are excited to be back to this year’s SITC (Free SITC Whitepaper) with our six groundbreaking studies that demonstrate the potential of our Lunit SCOPE suite in guiding treatment strategies for NSCLC and TNBC. We’ve also found valuable biomarkers and correlations that could lead to predictive information about patients’ immune response and the metastatic potential of the cancer tumor," said Brandon Suh, CEO of Lunit. "Through our participation in the SITC (Free SITC Whitepaper) conference, we will continue to back the efficacy of our Lunit SCOPE suite. At the same time, we are committed to seeking collaborations with healthcare giants worldwide to further our mission of advancing tailored cancer treatment."
Visit Lunit’s booth at SITC (Free SITC Whitepaper) 2023 at Booth #227 to learn more about these pioneering studies. To schedule a meeting with the Lunit team, please reach out to [email protected].
Lunit’s Abstracts at SITC (Free SITC Whitepaper) 2023
No.
Abstract
No. #
Title
Type
1
202
Spatial analysis of tumor-infiltrating lymphocytes in tumor microenvironment in non-small cell lung cancer patients who have resistance after EGFR tyrosine kinase inhibitors
Poster
2
961
Tumor-infiltrating lymphocytes in tumor microenvironment assessed by artificial intelligence powered H&E image analyzer is correlated with immunomodulatory subtype of triple-negative breast cancer
Poster
3
1446
Pan-cancer methylation analysis reveals a significant correlation of immune-desert phenotype with methylation aberrancy
Poster
4
1293
Fragmented pattern of tumor mass is related to fibroblast activation mitigating spatial interaction between tumor and immune cells
Poster
5
1308
Artificial intelligence (AI)-powered immune phenotyping based on programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) in triple negative breast cancer (TNBC)
Poster
6
614
Safety and efficacy of YBL-006, a novel anti-PD-1 antibody, in advanced solid tumors including G3 NET/NEC: Results from a phase 1/2a study
Poster